HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS ADCM SASDATA 9.4 Linux 18NOV21:22:15:1518NOV21:22:15:15 HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000011400000000000000000000 STUDYID Study Identifier USUBJID Unique Subject Identifier SUBJID Subject Identifier for the Study SITEID Study Site Identifier &CMSEQ Sequence Number *CMCAT Category for Medication 2CMSCAT Subcategory for Medication A CMSTDTC Start Date/Time of Medication B CMENDTC End Date/Time of Medication LJ CMTRT Reported Name of Drug, Med, or Therapy VL CMDECOD Standardized Medication Name  CMCODE Standardized Medication Code  PREFL Pre-treatment Flag ONPERFL On-Period Flag ONTR01FLOn-Period 01 Flag ONTR02FLOn-Period 02 Flag ASTDT Analysis Start Date DATE ASTDTF Analysis Start Date Imputation Flag ASTDY Analysis Start Relative Day AENDT Analysis End Date DATE  AENDTF Analysis End Date Imputation Flag AENDY Analysis End Relative Day CMCLAS Medication Class CMCLASCDMedication Class Code 4LDRUGNAMEWHODrug preferred name 9ATC1CD ATC Level 1 Code ?ATC1T ATC Level 1 Text ATC2CD ATC Level 2 Code @ATC2T ATC Level 2 Text ATC3CD ATC Level 3 Code 'ATC3T ATC Level 3 Text   ATC4CD ATC Level 4 Code 3!ATC4T ATC Level 4 Text 8"ATC5CD ATC Level 5 Code VR#ATC5T ATC Level 5 Text ]$CMSTDY Study Day of Start of Medication %CMENDY Study Day of End of Medication &CMDOSE Dose per Administration 'CMROUTE Route of Administration (CMDOSTXTDose Description )CMDOSU Dose Units *CMDOSFRQDosing Frequency per Interval +CMENRTPTEnd Relative to Reference Time Point ,CMENTPT End Reference Time Point -EPOCH Epoch .DICTVER Dictionary Name and Version /AGE Age 0AGEU Age Units 1SEX Sex  2SEXN Sex (N) ! 3RACE Race )4RACEN Race (N) I 5ARACE Analysis Race Q6ARACEN Analysis Race (N) q7SAFFL Safety Population Flag y8ARM Description of Planned Arm z 9ARMCD Planned Arm Code :ACTARM Description of Actual Arm  ;ACTARMCDActual Arm Code TRTSDTM Datetime of First Exposure to Treatment DATETIME ?TRTEDT Date of Last Exposure to Treatment DATE @TRTETM Time of Last Exposure to Treatment TIME  ATRTEDTM Datetime of Last Exposure to Treatment DATETIME BV01DT Date of Unblinding or Visit at 1MPD2 DATE CV02DT Date of Unblinding or Visit at 6MPD2 DATE DV03DT Date of Visit at 1M after Vax3/4 DATE EV04DT Date of Visit at 6M after Vax3/4 DATE  FVAX101DTVaccination Date 01 DATE GVAX10UDTVaccination Date Unplanned DATE HVAX102DTVaccination Date 02 DATE "IVAX201DTVaccination Date 03 DATE *JVAX202DTVaccination Date 04 DATE 2KCOHORTN Cohort Group (N) :LCOHORT Cohort Group BMDOSALVLNActual Dosing Level (N) CNDOSALVL Actual Dosing Level KODOSPLVLNPlanned Dosing Level (N) LPDOSPLVL Planned Dosing Level TQPHASEN Study Phase (N) URPHASE Study Phase ]SUNBLNDDTTreatment Unblinded Date DATE dTDS30KFL Phase 3 30k Subjects Flag lUHIVFL HIV Positive Subjects Flag mVAGETR01 Age at Vaccination 01 n WAGEGR1 Pooled Age Group 1 vXAGEGR1N Pooled Age Group 1 (N)  YAGEGR4 Pooled Age Group 4 ZAGEGR4N Pooled Age Group 4 (N) [TR01SDTMDatetime of First Exposure in Period 01 DATETIME \TR01EDTMDatetime of Last Exposure in Period 01 DATETIME ]TR02SDTMDatetime of First Exposure in Period 02 DATETIME ^TR02EDTMDatetime of Last Exposure in Period 02 DATETIME _TRT01A Actual Treatment for Period 01 `TRT01AN Actual Treatment for Period 01 (N) aTRT01P Planned Treatment for Period 01 bTRT01PN Planned Treatment for Period 01 (N) cTRT02A Actual Treatment for Period 02 dTRT02AN Actual Treatment for Period 02 (N) eTRT02P Planned Treatment for Period 02 %fTRT02PN Planned Treatment for Period 02 (N) @$gVAX101 Vaccination 01 H$hVAX102 Vaccination 02 liVAX10U Vaccination Unplanned $jVAX201 Vaccination 03 $kVAX202 Vaccination 04 lVAX20U Vaccination Unplanned in Period 02 mVAX20UDTVaccination Date Unplanned in Period 02 DATE nDS3KFL FU to 6MPD2 oRANDFL Randomized Population Flag )pVPHASE Vaccine Phase qVPHASEN Vaccine Phase(N)  rVAXNO CM Occured after Which Vaccination  HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1005 10051413100514131005AVACCINATIONS 2021-06-09 Meningococcal Vac MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr(DW DHrDW(DWb..DV.DW ... . . A@Phase 3DWcNNA12-15 YearsA12-15 YearsAHr(Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1006 10061242100612421006AVACCINATIONS 2020-11-25 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWD~THrDW%DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1006 10061242100612421006AVACCINATIONS 2020-11-25 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWD~THrDW%DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1006 10061242100612421006AVACCINATIONS 2020-11-25 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWD~THrDW%DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1006 10061265100612651006AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHru DWD{ Hrp DW+DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHru Hrp ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1006 10061265100612651006AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHru DWD{ Hrp DW+DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHru Hrp ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1006 10061265100612651006AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHru DWD{ Hrp DW+DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHru Hrp ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1006 10061265100612651006A VACCINATIONS 2021-05-13 Pfizer COVID VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHru DWD{ Hrp DW+DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHru Hrp ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1006 10061287100612871006AVACCINATIONS 2021-05-14 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHr̄xDW/DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr̄x..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1006 10061293100612931006AVACCINATIONS 2021-02-02 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW) B+. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B+.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHr`DW1DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr`..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1006 10061293100612931006AVACCINATIONS 2021-02-02 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW) B+. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B+.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHr`DW1DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr`..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1006 10061293100612931006AVACCINATIONS 2021-02-02 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW) B+. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B+.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHr`DW1DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr`..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1007 10071415100714151007AVACCINATIONS 2020-11-06 Human papillomavirus vaccine HPV VACCINE 06788701001 YY DV B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrayDVDHrDWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrayHr..Placebo APlacebo A . .Placebo Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071415100714151007AVACCINATIONS 2020-11-06 Human papillomavirus vaccine HPV VACCINE 06788701001 YY DV B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrayDVDHrDWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrayHr..Placebo APlacebo A . .Placebo Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071415100714151007AVACCINATIONS 2020-11-06 Human papillomavirus vaccine HPV VACCINE 06788701001 YY DV B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrayDVDHrDWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrayHr..Placebo APlacebo A . .Placebo Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071415100714151007A VACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrayDVDHrDWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrayHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071415100714151007A0VACCINATIONS 2021-05-13 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrayDVDHrDWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrayHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071417100714171007AVACCINATIONS 2020-10-03 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDPHraPDVDHr}#tDVDW?..DV.DV... . . A@Phase 3DW@NNA12-15 YearsA12-15 YearsAHraPHr}#t..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1007 10071417100714171007AVACCINATIONS 2020-10-03 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDPHraPDVDHr}#tDVDW?..DV.DV... . . A@Phase 3DW@NNA12-15 YearsA12-15 YearsAHraPHr}#t..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1007 10071417100714171007AVACCINATIONS 2020-10-03 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDPHraPDVDHr}#tDVDW?..DV.DV... . . A@Phase 3DW@NNA12-15 YearsA12-15 YearsAHraPHr}#t..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1007 10071428100714281007AVACCINATIONS 2021-05-15 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHraDVDHr}YDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHr}Y..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071428100714281007A VACCINATIONS 2021-06-05 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHraDVDHr}YDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHr}Y..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071429100714291007AVACCINATIONS 2020-09-25 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHraDVD`Hr}\DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHr}\..Placebo APlacebo A . .Placebo Placebo .NYPre-Vaccination .C4591001C4591001 1007 10071429100714291007AVACCINATIONS 2020-09-25 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHraDVD`Hr}\DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHr}\..Placebo APlacebo A . .Placebo Placebo .NYPre-Vaccination .C4591001C4591001 1007 10071429100714291007AVACCINATIONS 2020-09-25 Influenza vaccination INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHraDVD`Hr}\DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHr}\..Placebo APlacebo A . .Placebo Placebo .NYPre-Vaccination .C4591001C4591001 1007 10071429100714291007A VACCINATIONS 2021-05-13 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHraDVD`Hr}\DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHr}\..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071429100714291007A0VACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHraDVD`Hr}\DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHr}\..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071492100714921007AVACCINATIONS 2021-05-13 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD8Hrs8DVD|Hr|DWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrs8Hr|..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071492100714921007A VACCINATIONS 2021-06-03 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD8Hrs8DVD|Hr|DWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrs8Hr|..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071499100714991007AVACCINATIONS 2021-06-04 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDVD(HrDWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071499100714991007A VACCINATIONS 2021-05-13 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDVD(HrDWDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071515100715151007AVACCINATIONS 2021-05-14 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrCDWDHrDW"DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrCHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071515100715151007A VACCINATIONS 2021-06-05 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrCDWDHrDW"DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrCHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071528100715281007AVACCINATIONS 2021-05-13 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWD@HryDW#DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHry..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071528100715281007A VACCINATIONS 2021-06-03 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWD@HryDW#DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHry..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071539100715391007AVACCINATIONS 2021-07-22 meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrTDWDˬHs<DW#DWDWDXsDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrTHrHsHs<Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1007 10071543100715431007AVACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD<Hr<DWDHHrDW#DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr<Hr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071543100715431007A VACCINATIONS 2021-05-13 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD<Hr<DWDHHrDW#DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr<Hr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071554100715541007AVACCINATIONS 2021-06-17 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrJdDWDټHr<DW$DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrJdHr<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071554100715541007A VACCINATIONS 2021-05-22 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrJdDWDټHr<DW$DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrJdHr<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071573100715731007AVACCINATIONS 2021-06-03 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDXHrXDW DHr'DW*DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrXHr'..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071593100715931007AVACCINATIONS 2021-01-21 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr͜DWDHr͜DW2DW2..DW..... . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHr͜Hr͜..Placebo APlacebo A . .Placebo .NYVaccination 1 AAC4591001C4591001 1007 10071601100716011007AVACCINATIONS 2021-05-13 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHr(DWD4HrDWSDW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071603100716031007AVACCINATIONS 2021-06-05 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHr DW>DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071604100716041007AVACCINATIONS 2021-05-13 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHr,DW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr,..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071604100716041007A VACCINATIONS 2021-06-12 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHr,DW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr,..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071618100716181007AVACCINATIONS 2021-05-13 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr[DWD0Hr֜DW?DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr[Hr֜..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071618100716181007A VACCINATIONS 2021-06-03 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr[DWD0Hr֜DW?DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr[Hr֜..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071635100716351007AVACCINATIONS 2021-05-12 SARS-CoV-2 mRNA vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DHrDW!DHrPDW=DW..DW .DW!... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrP..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071654100716541007AVACCINATIONS 2021-05-17 SARS-CoV-2 vaccination Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW D(HrkDW"DHr"DW>DW..DW .DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrkHr"..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDW B. .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF03poliomyelitis, trivalent, inactivated, whole virus B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr{DWDhHs;hDW?DWDWDXcDW.DW#DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr*Hsr<Hs;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDW B. .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF04poliomyelitis oral, bivalent, live attenuated B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr{DWDhHs;hDW?DWDWDXcDW.DW#DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr*Hsr<Hs;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDW B. .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF02poliomyelitis oral, trivalent, live attenuated B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr{DWDhHs;hDW?DWDWDXcDW.DW#DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr*Hsr<Hs;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071655100716551007AVACCINATIONS 2021-07-02 Human poliovirus antigen-containing vaccine product POLIO VACCINE 06439201001 Y YDW B. .POLIOMYELITIS VACCINES J07BFPOLIO VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BFPOLIOMYELITIS VACCINES J07BF01poliomyelitis oral, monovalent, live attenuated B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr{DWDhHs;hDW?DWDWDXcDW.DW#DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr*Hsr<Hs;hPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1007 10071662100716621007AVACCINATIONS 2021-06-05 SARS-CoV-2 antigen vaccine Pfizer TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr)$DW$DLHr|LDW@DW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr)$Hr|L..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081758100817581008AVACCINATIONS 2021-05-27 meningitis B vaccine prophylaxis 0.5 mL intramuscular once MENINGOCOCCAL VACCINE B 06559312001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHrDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081769100817691008AVACCINATIONS 2021-06-03 menactra prophylaxis 0.5 mL intramuscular route once MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrPDWDHrDW>DWu..DV.DW... . . A@Phase 3DWvNNA12-15 YearsA12-15 YearsAHrPHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081775100817751008AVACCINATIONS 2020-11-16 Influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD<Hr<DWDHsHDW$DWDWDXnDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr<HrHsw HsHPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1008 10081775100817751008AVACCINATIONS 2020-11-16 Influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD<Hr<DWDHsHDW$DWDWDXnDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr<HrHsw HsHPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1008 10081775100817751008AVACCINATIONS 2020-11-16 Influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD<Hr<DWDHsHDW$DWDWDXnDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr<HrHsw HsHPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1008 10081790100817901008AVACCINATIONS 2021-03-16 HPV vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DWS B]. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B].. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrlDWDHs͐DW)DWDWDX_DV.DW DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrlHrxHslHs͐Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081790100817901008AVACCINATIONS 2021-03-16 HPV vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DWS B]. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B].. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrlDWDHs͐DW)DWDWDX_DV.DW DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrlHrxHslHs͐Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081790100817901008AVACCINATIONS 2021-03-16 HPV vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DWS B]. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B].. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrlDWDHs͐DW)DWDWDX_DV.DW DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrlHrxHslHs͐Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081815100818151008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BN.. FOLLOW-UP WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHsdDW,DWDWDXfDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrhHsv]HsdPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081815100818151008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BN.. FOLLOW-UP WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHsdDW,DWDWDXfDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrhHsv]HsdPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081815100818151008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BN.. FOLLOW-UP WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHsdDW,DWDWDXfDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrhHsv]HsdPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081816100818161008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BN.. FOLLOW-UP WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDdHrDWDHriDW,DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHri..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1008 10081816100818161008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BN.. FOLLOW-UP WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDdHrDWDHriDW,DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHri..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1008 10081816100818161008AVACCINATIONS 2021-03-05 influenza vaccine prophylaxis intramuscular 0.5 ml once INFLUENZA VACCINE 01389801001 YY DWH BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BN.. FOLLOW-UP WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDdHrDWDHriDW,DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHri..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1008 10081837100818371008AVACCINATIONS 2021-03-17 Gardasil #2 prophylaxis 0.5 ml intramuscular once HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DWT BV. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BV.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDPHr DWDHsDW3DWDWDXeDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr HrͷDHsuPHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081849100818491008AVACCINATIONS 2021-06-30 2nd HPV Vaccine prophylaxis 0.5 mL intramuscular route once HPV VACCINE 06788701001 Y YDW B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD\Hr#\DWD Hs DW9DWDWDX`DW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr#\Hr5xHsnzHs Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1008 10081849100818491008AVACCINATIONS 2021-06-30 2nd HPV Vaccine prophylaxis 0.5 mL intramuscular route once HPV VACCINE 06788701001 Y YDW B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD\Hr#\DWD Hs DW9DWDWDX`DW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr#\Hr5xHsnzHs Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1008 10081849100818491008AVACCINATIONS 2021-06-30 2nd HPV Vaccine prophylaxis 0.5 mL intramuscular route once HPV VACCINE 06788701001 Y YDW B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD\Hr#\DWD Hs DW9DWDWDX`DW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr#\Hr5xHsnzHs Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1008 10081872100818721008AVACCINATIONS 2021-03-19 Menactra prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DWV BP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBP.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrXDW~DHsYmDW:DWhDWDX;DW.DWDWkDW~. . . A@Phase 3DWiNNA12-15 YearsA12-15 YearsAHrXHr$Hs@bDHsYmPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081872100818721008A VACCINATIONS 2021-03-19 Trumenba prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE B RFHBPA/FHBPB 06559313001 YY DWV BP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBPA/FHBPB JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine BP.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrXDW~DHsYmDW:DWhDWDX;DW.DWDWkDW~. . . A@Phase 3DWiNNA12-15 YearsA12-15 YearsAHrXHr$Hs@bDHsYmPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1008 10081878100818781008AVACCINATIONS 2021-06-29 immunoglobulin prophylaxis once-dose, units and route unknown IMMUNOGLOBULINS NOS 07494701001 YY DW B. . IMMUNOGLOBULINS NOS JANTIINFECTIVES FOR SYSTEMIC USE J06IMMUNE SERA AND IMMUNOGLOBULINS J06BIMMUNOGLOBULINS B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDθHr8DWD$Hr6$DW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr8Hr6$..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008A VACCINATIONS 2021-06-26 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DW B. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDθHr8DWD$Hr6$DW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr8Hr6$..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008A0VACCINATIONS 2021-06-29 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DW B. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDθHr8DWD$Hr6$DW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr8Hr6$..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008A@VACCINATIONS 2021-07-03 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DW B. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDθHr8DWD$Hr6$DW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr8Hr6$..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081878100818781008APVACCINATIONS 2021-07-11 rabies vaccine 1.0 mL intramuscular route once RABIES VACCINE 00141201001 YY DW B. .RABIES VACCINES J07BGRABIES VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BGRABIES VACCINES J07BG01rabies, inactivated, whole virus B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDθHr8DWD$Hr6$DW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr8Hr6$..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081879100818791008AVACCINATIONS 2021-05-21 PFIZER COVID 19 VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrdDWDHrDW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrdHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081879100818791008A VACCINATIONS 2021-06-12 PFIZER COVID VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrdDWDHrDW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrdHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedBd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008AVACCINATIONS 2021-04-14 meningococcal vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE 06559301001 Y YDWp Bd. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081901100819011008A VACCINATIONS 2021-04-14 tetanus vaccination prophylaxis intramuscular 0.5 ml once TETANUS VACCINE 01594701001 Y YDWp Bd. .TETANUS VACCINES J07AMTETANUS VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AMTETANUS VACCINES J07AM01tetanus toxoid Bd.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DИHrtDWKDXHs%DW2DW2DWgDWDW .DW"DW6DWK. . . A@Phase 3DW3NNA12-15 YearsA12-15 YearsAHrtHr$LHrK8Hs%Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008AVACCINATIONS 2021-07-15 meningococcal conjugate mcv4 vaccine prophylaxis 0.5 mL intramuscular onceMENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081912100819121008A VACCINATIONS 2021-07-15 t-dap vaccine prophylaxis 0.5 mL intramuscular once DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOID13948907001 YY DW B. .PERTUSSIS VACCINES J07AJDIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOIDJANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AJPERTUSSIS VACCINES J07AJ52pertussis, purified antigen, combinations with toxoids B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD4Hr4DW$D,Hr,DWADW..DW.DW$... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1008 10081924100819241008AVACCINATIONS 2021-02-11 human papillomavirus vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DW2 B#. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B#.. VACCINATION WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr0DWDXHs DWADWDWDX`DW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr0HrlHsnHHs Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1008 10081924100819241008AVACCINATIONS 2021-02-11 human papillomavirus vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DW2 B#. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B#.. VACCINATION WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr0DWDXHs DWADWDWDX`DW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr0HrlHsnHHs Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1008 10081924100819241008AVACCINATIONS 2021-02-11 human papillomavirus vaccine prophylaxis intramuscular 0.5 ml once HPV VACCINE 06788701001 YY DW2 B#. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B#.. VACCINATION WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr0DWDXHs DWADWDWDX`DW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr0HrlHsnHHs Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1008 10081935100819351008AVACCINATIONS 2021-02-25 menactra vaccine prophylaxis intramuscular 0.5 ml once MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DW@ B.. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB... VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD<Hr^DW*D(Hr(DWEDWE..DW.DW*... . . A@Phase 3DWFNNA12-15 YearsA12-15 YearsAHr^Hr(..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091205100912051009AVACCINATIONS 2021-01-15 Tdap Vaccine DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOID13948907001 YY DW B]. .PERTUSSIS VACCINES J07AJDIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOIDJANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AJPERTUSSIS VACCINES J07AJ52pertussis, purified antigen, combinations with toxoids B].. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDXHrX>DVDHruu DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX>Hruu ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1009 10091208100912081009AVACCINATIONS 2020-12-04 flu vaccine INFLUENZA VACCINE 01389801001 YY DV B3. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B3.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDpHrXDDW\DxHs,xDVDW<DWyDXDV.DVDWHDW\. . . A@Phase 3DW=NNA12-15 YearsA12-15 YearsAHrXDHruHsDHs,xPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091208100912081009AVACCINATIONS 2020-12-04 flu vaccine INFLUENZA VACCINE 01389801001 YY DV B3. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B3.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDpHrXDDW\DxHs,xDVDW<DWyDXDV.DVDWHDW\. . . A@Phase 3DW=NNA12-15 YearsA12-15 YearsAHrXDHruHsDHs,xPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091208100912081009AVACCINATIONS 2020-12-04 flu vaccine INFLUENZA VACCINE 01389801001 YY DV B3. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B3.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDpHrXDDW\DxHs,xDVDW<DWyDXDV.DVDWHDW\. . . A@Phase 3DW=NNA12-15 YearsA12-15 YearsAHrXDHruHsDHs,xPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091216100912161009AVACCINATIONS 2020-11-30 Seasonal Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B... VACCINATION WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHHrYHDVDHru-DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrYHHru-..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091216100912161009AVACCINATIONS 2020-11-30 Seasonal Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B... VACCINATION WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHHrYHDVDHru-DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrYHHru-..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091216100912161009AVACCINATIONS 2020-11-30 Seasonal Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B.. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B... VACCINATION WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHHrYHDVDHru-DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrYHHru-..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1009 10091246100912461009AVACCINATIONS 2020-12-07 HPV VACCINE HPV VACCINE 06788701001 YY DV B/. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B/.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHraxDWD0HsDVDWDWDXdDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraxHrzHssHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009AVACCINATIONS 2020-12-07 HPV VACCINE HPV VACCINE 06788701001 YY DV B/. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B/.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHraxDWD0HsDVDWDWDXdDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraxHrzHssHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009AVACCINATIONS 2020-12-07 HPV VACCINE HPV VACCINE 06788701001 YY DV B/. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B/.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHraxDWD0HsDVDWDWDXdDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraxHrzHssHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009A VACCINATIONS 2020-12-07 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001 YY DV B/. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B/.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHraxDWD0HsDVDWDWDXdDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraxHrzHssHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009A VACCINATIONS 2020-12-07 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001 YY DV B/. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B/.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHraxDWD0HsDVDWDWDXdDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraxHrzHssHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091246100912461009A VACCINATIONS 2020-12-07 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001 YY DV B/. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B/.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHraxDWD0HsDVDWDWDXdDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraxHrzHssHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091301100913011009AVACCINATIONS 2021-04-28 MCV4 MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW~ B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDLHrfLDWD(Hs(DW$DWDWDXqDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrfLHrHskHs(Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091311100913111009AVACCINATIONS 2020-11-20 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWDxHs^DW!DWDWDXdDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrDHsr8Hs^Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1009 10091311100913111009AVACCINATIONS 2020-11-20 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWDxHs^DW!DWDWDXdDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrDHsr8Hs^Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1009 10091311100913111009AVACCINATIONS 2020-11-20 INFLUENZA VACCINE INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWDxHs^DW!DWDWDXdDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrDHsr8Hs^Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1009 10091378100913781009AVACCINATIONS 2021-03-30 HPV9 HPV VACCINE 06788701001 YY DWa Bd. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Bd.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD Hr DWDHs0DW6DWDXDXDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr HroHsαHs0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091378100913781009AVACCINATIONS 2021-03-30 HPV9 HPV VACCINE 06788701001 YY DWa Bd. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) Bd.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD Hr DWDHs0DW6DWDXDXDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr HroHsαHs0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1009 10091378100913781009AVACCINATIONS 2021-03-30 HPV9 HPV VACCINE 06788701001 YY DWa Bd. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) Bd.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD Hr DWDHs0DW6DWDXDXDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr HroHsαHs0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1013 10131839101318391013AVACCINATIONS 2021-07-02 PFIZER BIONTECH COVID 19 VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDTHrDWD HrP DWDW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrP ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1016 10161310101613101016AVACCINATIONS 2020-12-02 fluzone, influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDԔHrX]DVD0HrrjDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX]Hrrj..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1016 10161310101613101016AVACCINATIONS 2020-12-02 fluzone, influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDԔHrX]DVD0HrrjDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX]Hrrj..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1016 10161310101613101016AVACCINATIONS 2020-12-02 fluzone, influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDԔHrX]DVD0HrrjDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX]Hrrj..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1016 10161320101613201016AVACCINATIONS 2020-10-05 Fluzone, influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDTHr` DVDHry DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr` Hry ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1016 10161320101613201016AVACCINATIONS 2020-10-05 Fluzone, influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDTHr` DVDHry DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr` Hry ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1016 10161320101613201016AVACCINATIONS 2020-10-05 Fluzone, influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDTHr` DVDHry DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr` Hry ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1016 10161334101613341016AVACCINATIONS 2020-09-12 flumist INFLUENZA VACCINE LIVE REASSORT 3V 01389809001Y DV '. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE LIVE REASSORT 3V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated '.. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDҴHr`D4DWDHslDVDWDWDXkDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`D4Hr|\Hs\HslPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016AVACCINATIONS 2020-09-18 Fluzone, Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV !. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated !.. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDDHr`YDWDHsiUDVDWXDWDXGDV.DVDWuDW. . . A@Phase 3DWYNNA12-15 YearsA12-15 YearsAHr`YHrz0HsMHsiUPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016AVACCINATIONS 2020-09-18 Fluzone, Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV !. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen !.. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDDHr`YDWDHsiUDVDWXDWDXGDV.DVDWuDW. . . A@Phase 3DWYNNA12-15 YearsA12-15 YearsAHr`YHrz0HsMHsiUPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016AVACCINATIONS 2020-09-18 Fluzone, Influenza Vaccine INFLUENZA VACCINE 01389801001Y DV !. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus !.. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDDHr`YDWDHsiUDVDWXDWDXGDV.DVDWuDW. . . A@Phase 3DWYNNA12-15 YearsA12-15 YearsAHr`YHrz0HsMHsiUPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1016 10161337101613371016A VACCINATIONS 2021-03-19 menactra MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DWV B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDDHr`YDWDHsiUDVDWXDWDXGDV.DVDWuDW. . . A@Phase 3DWYNNA12-15 YearsA12-15 YearsAHr`YHrz0HsMHsiUPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1016 10161337101613371016A0VACCINATIONS 2021-03-19 trumenba MENINGOCOCCAL VACCINE B RFHBPA/FHBPB 06559313001 YY DWV B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBPA/FHBPB JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDDHr`YDWDHsiUDVDWXDWDXGDV.DVDWuDW. . . A@Phase 3DWYNNA12-15 YearsA12-15 YearsAHr`YHrz0HsMHsiUPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1016 10161343101613431016AVACCINATIONS 2020-09-21 flucelvax quadrivalent INFLUENZA VACCINE INACT SAG 4V 01389812001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SAG 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD$Hra$DVDHr~DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHra$Hr~..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1039 10391295103912951039AVACCINATIONS 2021-07-26 Bexsero (Meningococcal B vaccine) MENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV 06559314001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDxHrDWDHrPDW>DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrP..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391295103912951039A VACCINATIONS 2021-07-26 Menactra (Meningococcal conjugate) MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDxHrDWDHrPDW>DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrP..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391297103912971039AVACCINATIONS 2021-04-30 gardasil, 0.5 mL, once, intramuscular HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW B{. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B{.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDxHrxDWDkHrփDW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrxHrփ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391300103913001039AVACCINATIONS 2021-06-24 Meningococcal vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWD(Hr(DWDsPHr.DW=DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr(Hr...BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391317103913171039AVACCINATIONS 2021-03-04 Gardasil Vaccine HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DWG B9. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B9.. FOLLOW-UP WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDĤHr $DWDrHsDWADWDWDX_DW.DW$DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr $HrPHsnHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1039 10391320103913201039AVACCINATIONS 2021-05-17 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr)DW%DHrلDWADW..DW.DW%... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr)Hrل..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391320103913201039A VACCINATIONS 2021-06-13 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr)DW%DHrلDWADW..DW.DW%... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr)Hrل..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391327103913271039AVACCINATIONS 2021-05-15 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW B}. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B}.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrE0DW(DzHrDWEDW..DW.DW(... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrE0Hr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1039 10391327103913271039A VACCINATIONS 2021-06-05 BNT162B2 Pfizer vaccine, once, intramuscular injection TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrE0DW(DzHrDWEDW..DW.DW(... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrE0Hr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1044 10441271104412711044AVACCINATIONS 2021-06-14 Pfizer Covid 19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHrDWDHrLDW%DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrL..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1044 10441271104412711044A VACCINATIONS 2021-05-24 Pfizer Covid 19 Vaccine( Non Study) TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDxHrDWDHrLDW%DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrL..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1044 10441290104412901044AVACCINATIONS 2020-11-23 GARDASIL HPV VACCINE VLP RL1 4V (YEAST) 06788703001Y DV .. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) ... SCREENING WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrZDW%DHr pDWADW..DW.DW%... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrZHr p..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441290104412901044A VACCINATIONS 2020-11-23 influenza INFLUENZA VACCINE 01389801001Y DV .. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated ... SCREENING WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrZDW%DHr pDWADW..DW.DW%... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrZHr p..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441290104412901044A VACCINATIONS 2020-11-23 influenza INFLUENZA VACCINE 01389801001Y DV .. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen ... SCREENING WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrZDW%DHr pDWADW..DW.DW%... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrZHr p..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441290104412901044A VACCINATIONS 2020-11-23 influenza INFLUENZA VACCINE 01389801001Y DV .. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus ... SCREENING WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrZDW%DHr pDWADW..DW.DW%... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrZHr p..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1044 10441293104412931044AVACCINATIONS 2021-06-04 Pfizer Covid 19 vaccine TOZINAMERAN 15268625001 Y YDW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVE7@HrtDWDHsnDW+DWDWDXbDV.DW DW.. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrtHrēHsnHsnPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 3 APA0C4591001C4591001 1044 10441294104412941044AVACCINATIONS 2021-06-04 Pfizer Covid 19 Vaccine TOZINAMERAN 15268625001 Y YDW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVE;HrDWDTHsnTDW+DWDWDXbDV.DW DW.. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrēDHsnTHsnTPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 3 APA0C4591001C4591001 1044 10441356104413561044AVACCINATIONS 2021-05-14 non-study COVID-19 Pfizer vaccine TOZINAMERAN 15268625001 YY DW B}. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B}.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrޘDW)DHrlDWKDW..DW.DW)... . . A@Phase 3.NNA12-15 YearsA12-15 YearsAHrޘHrl..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1044 10441356104413561044A VACCINATIONS 2021-06-04 non-study COVID-19 Pfizer vaccines TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrޘDW)DHrlDWKDW..DW.DW)... . . A@Phase 3.NNA12-15 YearsA12-15 YearsAHrޘHrl..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1057 10571389105713891057AVACCINATIONS 2021-06-12 PFIZER BNT162B2 TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4Hr4DW DHr<DW*DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1057 10571389105713891057A VACCINATIONS 2021-05-23 PFIZER BNT162b2 TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4Hr4DW DHr<DW*DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1066 10661394106613941066AVACCINATIONS 2020-11-24 influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4Hr4DWDHsDW#DWDWDXkDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr]dHssq\HsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1066 10661394106613941066AVACCINATIONS 2020-11-24 influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4Hr4DWDHsDW#DWDWDXkDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr]dHssq\HsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1066 10661394106613941066AVACCINATIONS 2020-11-24 influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4Hr4DWDHsDW#DWDWDXkDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr]dHssq\HsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1077 10771282107712821077AVACCINATIONS 2021-05-15 PFIZER COVID-19 VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrpDW DHrČ<DW+DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrpHrČ<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1077 10771289107712891077AVACCINATIONS 2021-05-14 PFIZER BNT162b2 COVID-19 VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWDPHrePDW3DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHreP..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1077 10771290107712901077AVACCINATIONS 2021-05-14 PFIZER BNT162b2 COVID-19 VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDXHrDWDHreDW3DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHre..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1084 10841542108415421084AVACCINATIONS 2021-05-18 Pfizer-BioNTech COVID-19 vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHrWDWDHrxDW%DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrWHrx..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1084 10841542108415421084A VACCINATIONS 2021-06-08 Pfizer-BioNTech COVID-19 vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHrWDWDHrxDW%DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrWHrx..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841571108415711084AVACCINATIONS 2021-05-07 Meningitis Vaccine MENINGOCOCCAL VACCINE 06559301001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHsDW=DWDWDXDW.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr?HswHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1084 10841579108415791084AVACCINATIONS 2021-05-14 Pfizer Covid-19 Vaccination TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrŽDW#D<HrᔼDW@DW..DW.DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrŽHrᔼ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911396109113961091AVACCINATIONS 2021-06-25 Meningitis vaccine MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHHrDWD(Hs (DWDWDWDX]DV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr4HskHs (Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1091 10911413109114131091AVACCINATIONS 2021-06-28 Gardasil vaccine HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW B. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD Hr DWDHrDW0DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911435109114351091AVACCINATIONS 2021-02-23 HPV vaccine HPV VACCINE 06788701001 YY DW> BE. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BE.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHr1DW+DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr1..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1091 10911435109114351091AVACCINATIONS 2021-02-23 HPV vaccine HPV VACCINE 06788701001 YY DW> BE. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) BE.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHr1DW+DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr1..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1091 10911435109114351091AVACCINATIONS 2021-02-23 HPV vaccine HPV VACCINE 06788701001 YY DW> BE. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) BE.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDHr1DW+DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr1..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1091 10911443109114431091AVACCINATIONS 2021-08-04 Tdap vaccine DIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOID13948907001 YY DW B. .PERTUSSIS VACCINES J07AJDIPHTHERIA VACCINE TOXOID;PERTUSSIS VACCINE ACELLULAR;TETANUS VACCINE TOXOIDJANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AJPERTUSSIS VACCINES J07AJ52pertussis, purified antigen, combinations with toxoids B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD8Hr8DWDHrR<DW3DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr8HrR<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911455109114551091AVACCINATIONS 2021-05-13 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHr֚DWADW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr֚..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911455109114551091A VACCINATIONS 2021-06-03 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrDWDHr֚DWADW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr֚..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911456109114561091AVACCINATIONS 2021-05-13 Pfizer covid-19 vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD0HrV0DWDHrՔDW6DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrV0HrՔ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911456109114561091A VACCINATIONS 2021-06-03 Pfizer covid-19 vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD0HrV0DWDHrՔDW6DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrV0HrՔ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911461109114611091AVACCINATIONS 2021-05-19 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrgDWDTHrDW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrgHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1091 10911461109114611091A VACCINATIONS 2021-06-09 Pfizer Covid-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWDHrgDWDTHrDW8DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrgHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1126 11261266112612661126AVACCINATIONS 2021-03-12 HPV9 vaccine HPV VACCINE 06788701001 YY DWO BY. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BY.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr)DWDHs> DW(DWDWDXjDV.DW DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr)Hr`HsuHs> Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261266112612661126AVACCINATIONS 2021-03-12 HPV9 vaccine HPV VACCINE 06788701001 YY DWO BY. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) BY.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr)DWDHs> DW(DWDWDXjDV.DW DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr)Hr`HsuHs> Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261266112612661126AVACCINATIONS 2021-03-12 HPV9 vaccine HPV VACCINE 06788701001 YY DWO BY. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) BY.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr)DWDHs> DW(DWDWDXjDV.DW DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr)Hr`HsuHs> Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261281112612811126AVACCINATIONS 2021-02-12 Fluarix Quadrivalent Influenza Vaccination INFLUENZA VACCINE INACT SPLIT 4V 01389806001 YY DW3 B;. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B;.. FOLLOW-UP WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDDWDdHr,DW3DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrDHr,..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1126 11261292112612921126AVACCINATIONS 2021-03-29 HPV9 HPV VACCINE 06788701001 YY DW` Bg. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Bg.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHsDW+DWDWDXcDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr+|HsrfHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261292112612921126AVACCINATIONS 2021-03-29 HPV9 HPV VACCINE 06788701001 YY DW` Bg. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) Bg.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHsDW+DWDWDXcDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr+|HsrfHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261292112612921126AVACCINATIONS 2021-03-29 HPV9 HPV VACCINE 06788701001 YY DW` Bg. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) Bg.. FOLLOW-UP WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHsDW+DWDWDXcDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr+|HsrfHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261320112613201126AVACCINATIONS 2021-04-13 HPV9 Vaccine HPV VACCINE 06788701001 YY DWo Ba. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) Ba.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr4dDWDƄHsqDW@DWDWDXdDW.DW$DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4dHrDHss HsqPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261320112613201126AVACCINATIONS 2021-04-13 HPV9 Vaccine HPV VACCINE 06788701001 YY DWo Ba. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) Ba.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr4dDWDƄHsqDW@DWDWDXdDW.DW$DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4dHrDHss HsqPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261320112613201126AVACCINATIONS 2021-04-13 HPV9 Vaccine HPV VACCINE 06788701001 YY DWo Ba. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) Ba.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHr4dDWDƄHsqDW@DWDWDXdDW.DW$DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4dHrDHss HsqPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1126 11261325112613251126AVACCINATIONS 2021-03-02 HPV (human Papillomavirus 9 valent) HPV VACCINE 06788701001 YY DWE B6. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B6.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrȍDWDǰHsr0DWEDWDWDXdDW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrȍHr+PHssHHsr0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1126 11261325112613251126AVACCINATIONS 2021-03-02 HPV (human Papillomavirus 9 valent) HPV VACCINE 06788701001 YY DWE B6. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B6.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrȍDWDǰHsr0DWEDWDWDXdDW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrȍHr+PHssHHsr0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1126 11261325112613251126AVACCINATIONS 2021-03-02 HPV (human Papillomavirus 9 valent) HPV VACCINE 06788701001 YY DWE B6. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B6.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrȍDWDǰHsr0DWEDWDWDXdDW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrȍHr+PHssHHsr0Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1131 11311275113112751131AVACCINATIONS 2021-08-27 flu vaccine INFLUENZA VACCINE 01389801001 YY DW C. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated C.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr,DWDHr-DWDW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr,Hr-..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1131 11311275113112751131AVACCINATIONS 2021-08-27 flu vaccine INFLUENZA VACCINE 01389801001 YY DW C. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen C.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr,DWDHr-DWDW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr,Hr-..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1131 11311275113112751131AVACCINATIONS 2021-08-27 flu vaccine INFLUENZA VACCINE 01389801001 YY DW C. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus C.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr,DWDHr-DWDW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr,Hr-..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391166113911661139AVACCINATIONS 2021-07-20 menactra MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWNDDHsDDW.DW.DWpDX DV.DWDW7DWN. . . A@Phase 3DW/NNA12-15 YearsA12-15 YearsAHrhHrHr(HsDPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1139 11391169113911691139AVACCINATIONS 2021-05-11 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHr7DW8DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr7..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1139 11391169113911691139A VACCINATIONS 2021-06-01 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DVDHrDWDHr7DW8DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr7..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391171113911711139AVACCINATIONS 2021-05-19 Pfizer, COVID-19 vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDPHrPDW DHrVTDWMDW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrPHrVT..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391171113911711139A VACCINATIONS 2021-06-09 Pfizer, COVID-19 vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDPHrPDW DHrVTDWMDW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrPHrVT..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1139 11391235113912351139AVACCINATIONS 2021-07-07 Menactra vaccine MENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) 06559309001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W CONJ (DIP TOX) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DHrďDWKDHsDW.DW.DWgDXDW .DW$DW6DWK. . . A@Phase 3DW/NNA12-15 YearsA12-15 YearsAHrďHrXHrHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DW BDW B PREDNISONE AALIMENTARY TRACT AND METABOLISM A07ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTSA07EINTESTINAL ANTIINFLAMMATORY AGENTS A07EACORTICOSTEROIDS ACTING LOCALLYA07EA03prednisone BBBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr DWDHrDW9DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DW BDW B PREDNISONE HSYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINSH02CORTICOSTEROIDS FOR SYSTEMIC USE H02ACORTICOSTEROIDS FOR SYSTEMIC USE, PLAINH02ABGLUCOCORTICOIDS H02AB07prednisone BBBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr DWDHrDW9DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DW BDW B PREDNISONE SSENSORY ORGANS S01OPHTHALMOLOGICALS S01BANTIINFLAMMATORY AGENTS S01BACORTICOSTEROIDS, PLAIN BBBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr DWDHrDW9DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401354114013541140ACORTICOSTEROIDS 2021-07-182021-07-31Prednisone Taper PREDNISONE 00044701001 YY DW BDW B PREDNISONE DDERMATOLOGICALS D07CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07ACORTICOSTEROIDS, PLAIN BBBORAL mgQD REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr DWDHrDW9DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr Hr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1140 11401357114013571140AVACCINATIONS 2021-05-13 Pfizer COVID-19 Vaccine Dose 1 TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDƄHrFDWDxHr^DW/DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrFHr^..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471261114712611147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDôHr4DW D`Hr`DW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr`..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471261114712611147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDôHr4DW D`Hr`DW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr`..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471261114712611147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDôHr4DW D`Hr`DW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4Hr`..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471262114712621147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr,DW D|Hr|DW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr,Hr|..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471262114712621147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr,DW D|Hr|DW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr,Hr|..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471262114712621147AVACCINATIONS 2020-11-23 Influenza vaccine INFLUENZA VACCINE 01389801001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus .. SCREENING WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr,DW D|Hr|DW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr,Hr|..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471269114712691147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$cDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr8HsHs$cPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471270114712701147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDhHrhDWVD@Hs$d@DW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrhHrؠHsHs$d@Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471271114712711147AVACCINATIONS 2021-05-26 Meningococcal Vaccine; 0.5 mL; IM MENINGOCOCCAL VACCINE 06559301001 Y YDW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. OPEN LABEL FOLLOW-UPWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDWVDHs$dDW&DW7DWuDXDV.DWDW?DWV. . . A@Phase 3DW8NNA12-15 YearsA12-15 YearsAHrHr޸HsHs$dPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA@C4591001C4591001 1147 11471284114712841147AVACCINATIONS 2021-05-30 BNT162b2 0.3mL IM TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDW DɐHrDW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471284114712841147A VACCINATIONS 2021-06-23 BNT162b2 0.3mL IM TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrDW DɐHrDW-DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471322114713221147AVACCINATIONS 2021-05-14 Non-study COVID-19 Vaccine (Pfizer) TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DHrtTDW#DHr'DWKDW..DW .DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrtTHr'..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471322114713221147A VACCINATIONS 2021-06-04 Non-study COVID-19 vaccine (Pfizer) TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DHrtTDW#DHr'DWKDW..DW .DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrtTHr'..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471323114713231147AVACCINATIONS 2021-05-14 Non-study COVID-19 Vaccine (Pfizer) TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DdHrĉDW#DHr4DW@DW..DW .DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrĉHr4..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471323114713231147A VACCINATIONS 2021-06-04 non study COVID-19 vaccine (pfizer) TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DW DdHrĉDW#DHr4DW@DW..DW .DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrĉHr4..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471327114713271147AVACCINATIONS 2021-05-07 BNT162b2 Dose #1 IM/once TOZINAMERAN 15268625001 YY DW B{. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B{.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW DhHrĔDW DhHrĔDW@DW..DW ..... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrĔHrĔ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0AC4591001C4591001 1147 11471327114713271147A VACCINATIONS 2021-06-04 BNT162b2 Dose #2 IM/once TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW DhHrĔDW DhHrĔDW@DW..DW ..... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrĔHrĔ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYAfter unblinding and before Vaccination 3A@AC4591001C4591001 1147 11471335114713351147AVACCINATIONS 2021-05-20 non study COVID-19 vaccine (pfizer) TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrŖDW#DHr$<DW@DW..DW.DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrŖHr$<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471335114713351147A VACCINATIONS 2021-06-10 non study COVID-19 vaccine (pfizer) TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrŖDW#DHr$<DW@DW..DW.DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrŖHr$<..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471336114713361147AVACCINATIONS 2021-07-22 BNT162B2 0.3 mL IM TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrŨDW#D@HrEDW@DW..DW.DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrŨHrE..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471336114713361147A VACCINATIONS 2021-08-12 BNT162B2 0.3 mL IM TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrŨDW#D@HrEDW@DW..DW.DW#... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrŨHrE..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1147 11471344114713441147AVACCINATIONS 2020-10 Flu vaccine INFLUENZA VACCINE 01389801001Y DVDa. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated ... WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW3DHrdDWODW..DW.DW3... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrd..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471344114713441147AVACCINATIONS 2020-10 Flu vaccine INFLUENZA VACCINE 01389801001Y DVDa. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen ... WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW3DHrdDWODW..DW.DW3... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrd..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471344114713441147AVACCINATIONS 2020-10 Flu vaccine INFLUENZA VACCINE 01389801001Y DVDa. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus ... WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW3DHrdDWODW..DW.DW3... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrd..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYPre-Vaccination .C4591001C4591001 1147 11471344114713441147A VACCINATIONS 2021-01-13 Gardasil HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW A. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) A.. VACCINATION WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW3DHrdDWODW..DW.DW3... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrd..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501118115011181150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDPHrX DVDHrqDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX Hrq..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501118115011181150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDPHrX DVDHrqDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX Hrq..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501118115011181150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDPHrX DVDHrqDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX Hrq..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501119115011191150AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B2.. FOLLOW-UP WHODDG B3 v202103AYEARSMAMULTIPLE A`MULTIRACIAL A`YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrX-DDVDǰHrsDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX-DHrs..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501119115011191150AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B2.. FOLLOW-UP WHODDG B3 v202103AYEARSMAMULTIPLE A`MULTIRACIAL A`YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrX-DDVDǰHrsDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX-DHrs..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501119115011191150AVACCINATIONS 2020-12-03 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B2.. FOLLOW-UP WHODDG B3 v202103AYEARSMAMULTIPLE A`MULTIRACIAL A`YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrX-DDVDǰHrsDVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrX-DHrs..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501121115011211150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4HrXqDWDXHs?DVDWDWDXfDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrXqHrq,Hsv6Hs?Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501121115011211150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4HrXqDWDXHs?DVDWDWDXfDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrXqHrq,Hsv6Hs?Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501121115011211150AVACCINATIONS 2020-12-02 influenza vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVD4HrXqDWDXHs?DVDWDWDXfDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrXqHrq,Hsv6Hs?Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501131115011311150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DV B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B5.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr_DWRDHsDVDW6DWnDXDV.DVDW>DWR. . . A@Phase 3DW7NNA12-15 YearsA12-15 YearsAHr_Hry HsPHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501131115011311150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DV B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B5.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr_DWRDHsDVDW6DWnDXDV.DVDW>DWR. . . A@Phase 3DW7NNA12-15 YearsA12-15 YearsAHr_Hry HsPHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501131115011311150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DV B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B5.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr_DWRDHsDVDW6DWnDXDV.DVDW>DWR. . . A@Phase 3DW7NNA12-15 YearsA12-15 YearsAHr_Hry HsPHsPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1150 11501132115011321150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DV B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B5.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr_DVD Hry DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr_Hry ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501132115011321150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DV B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B5.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr_DVD Hry DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr_Hry ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501132115011321150AVACCINATIONS 2020-12-11 Flu Vaccine INFLUENZA VACCINE 01389801001 YY DV B5. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B5.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr_DVD Hry DVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr_Hry ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501133115011331150AVACCINATIONS 2020-12-08 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr_pDVDHrzdDVDW1..DV.DV... . . A@Phase 3DW2NNA12-15 YearsA12-15 YearsAHr_pHrzd..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501133115011331150AVACCINATIONS 2020-12-08 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr_pDVDHrzdDVDW1..DV.DV... . . A@Phase 3DW2NNA12-15 YearsA12-15 YearsAHr_pHrzd..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501133115011331150AVACCINATIONS 2020-12-08 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DV B1. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B1.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr_pDVDHrzdDVDW1..DV.DV... . . A@Phase 3DW2NNA12-15 YearsA12-15 YearsAHr_pHrzd..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501171115011711150AVACCINATIONS 2021-09-01 Pfizer BNT162b2 Comirnaty COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW C. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES C.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDWDXHriDW!DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHri..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1150 11501178115011781150AVACCINATIONS 2021-02-22 Gardasil Vaccine HPV VACCINE VLP RL1 4V (YEAST) 06788703001 YY DW= BN. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE VLP RL1 4V (YEAST) JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) BN.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD\Hr\DWDdHr DW"DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr\Hr ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501178115011781150A VACCINATIONS 2021-02-22 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW= BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BN.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD\Hr\DWDdHr DW"DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr\Hr ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501178115011781150A VACCINATIONS 2021-02-22 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW= BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BN.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD\Hr\DWDdHr DW"DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr\Hr ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501178115011781150A VACCINATIONS 2021-02-22 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW= BN. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BN.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD\Hr\DWDdHr DW"DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr\Hr ..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1150 11501213115012131150AVACCINATIONS 2021-02-04 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW+ B4. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated B4.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDW DHrDW+DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501213115012131150AVACCINATIONS 2021-02-04 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW+ B4. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B4.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDW DHrDW+DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501213115012131150AVACCINATIONS 2021-02-04 Influenza Vaccine INFLUENZA VACCINE 01389801001 YY DW+ B4. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus B4.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHrDW DHrDW+DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501273115012731150AVACCINATIONS 2021-02-23 HPV Vaccine HPV VACCINE 06788701001 YY DW> B2. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) B2.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW DHr&HDW"DzHr͔DW?DW..DW .DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr&HHr͔..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501273115012731150AVACCINATIONS 2021-02-23 HPV Vaccine HPV VACCINE 06788701001 YY DW> B2. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) B2.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW DHr&HDW"DzHr͔DW?DW..DW .DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr&HHr͔..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501273115012731150AVACCINATIONS 2021-02-23 HPV Vaccine HPV VACCINE 06788701001 YY DW> B2. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) B2.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DW DHr&HDW"DzHr͔DW?DW..DW .DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr&HHr͔..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedAP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1150 11501293115012931150AVACCINATIONS 2021-01-15 Meningitis Vaccines MENINGOCOCCAL VACCINE 06559301001 YY DW AP. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated AP.. VACCINATION WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHr4PDW3DHrtDWCDWC..DW.DW3... . . A@Phase 3DWDNNA12-15 YearsA12-15 YearsAHr4PHrt..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1152 11521698115216981152AVACCINATIONS 2021-05-15 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrxDWDTHraTDW/DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrxHraT..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1152 11521726115217261152AVACCINATIONS 2021-06-12 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA ASIAN A@ASIAN A@YPlacebo PLACEBO Placebo PLACEBO DWD`HrDWD,Hrթ,DW6DW..DW.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrթ,..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1152 11521747115217471152AVACCINATIONS 2021-07-20 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 Y YDW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrȄDWDHsv~DWKDWDWDXhDW.DW#DW.. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrȄHr^\Hsv~Hsv~Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 3 ApA0C4591001C4591001 1152 11521751115217511152AVACCINATIONS 2021-05-17 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD|Hr 0DW)DHr DWEDW..DW.DW)... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr 0Hr ..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1152 11521754115217541152AVACCINATIONS 2021-05-20 Pfizer COVID-19 Vaccine TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDHrxHDW(DHrDWDDW..DW.DW(... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrxHHr..Placebo APlacebo A . .Placebo Placebo .NYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561246115612461156AVACCINATIONS 2020-09-23 HPV 9 HPV VACCINE 06788701001Y DV . .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) .. SCREENING WHODDG B3 v202103AYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVDHraDWDPHsPDVDWDWDXgDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHrziHsw4HsPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561246115612461156AVACCINATIONS 2020-09-23 HPV 9 HPV VACCINE 06788701001Y DV . .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) .. SCREENING WHODDG B3 v202103AYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVDHraDWDPHsPDVDWDWDXgDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHrziHsw4HsPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561246115612461156AVACCINATIONS 2020-09-23 HPV 9 HPV VACCINE 06788701001Y DV . .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) .. SCREENING WHODDG B3 v202103AYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVDHraDWDPHsPDVDWDWDXgDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHrziHsw4HsPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561246115612461156A VACCINATIONS 2020-09-23 MEN B (BEXSERO) MENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV 06559314001Y DV . .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE B RFHBP/NADA/NHBA OMV JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine .. SCREENING WHODDG B3 v202103AYEARSMABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YPlacebo PLACEBO Placebo PLACEBO DVDHraDWDPHsPDVDWDWDXgDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHraHrziHsw4HsPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1156 11561257115612571156AVACCINATIONS 2021-01-04 INFLUENZA VACCINE, ARM, SIDE(UNKNOWN), ROUTE(UNKNOWN). INFLUENZA VACCINE 01389801001 YY DW BM. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB03influenza, live attenuated BM.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr^DVD0Hr}ADVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr^Hr}A..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1156 11561257115612571156AVACCINATIONS 2021-01-04 INFLUENZA VACCINE, ARM, SIDE(UNKNOWN), ROUTE(UNKNOWN). INFLUENZA VACCINE 01389801001 YY DW BM. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen BM.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr^DVD0Hr}ADVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr^Hr}A..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1156 11561257115612571156AVACCINATIONS 2021-01-04 INFLUENZA VACCINE, ARM, SIDE(UNKNOWN), ROUTE(UNKNOWN). INFLUENZA VACCINE 01389801001 YY DW BM. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB01influenza, inactivated, whole virus BM.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDHr^DVD0Hr}ADVDW..DV.DV... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr^Hr}A..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561263115612631156AVACCINATIONS 2021-05-10 MENINGOCCAL CONJUGATE VACCINE MENINGOCOCCAL VACCINE CONJ 06559320001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE CONJ JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. FOLLOW-UP WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr`HlDWD|Hs4DVDWDWDXjDV.DVDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr`HlHrzhHs|Hs4Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYFollow Up 1 A0A C4591001C4591001 1156 11561310115613101156AVACCINATIONS 2020-12-08 9-VAKENT HUMAN PAPILLOMAVIRUS VACCINE HPV VACCINE 06788701001 YY DV A. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM01papillomavirus (human types 6, 11, 16, 18) A.. VACCINATION WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD$Hri$DWDHrېDW,DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHri$Hrې..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1156 11561310115613101156AVACCINATIONS 2020-12-08 9-VAKENT HUMAN PAPILLOMAVIRUS VACCINE HPV VACCINE 06788701001 YY DV A. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM03papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) A.. VACCINATION WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD$Hri$DWDHrېDW,DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHri$Hrې..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1156 11561310115613101156AVACCINATIONS 2020-12-08 9-VAKENT HUMAN PAPILLOMAVIRUS VACCINE HPV VACCINE 06788701001 YY DV A. .PAPILLOMAVIRUS VACCINESJ07BMHPV VACCINE JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BMPAPILLOMAVIRUS VACCINES J07BM02papillomavirus (human types 16, 18) A.. VACCINATION WHODDG B3 v202103AYEARSFA BLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICAN A YBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVD$Hri$DWDHrېDW,DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHri$Hrې..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 1 AAC4591001C4591001 1156 11561336115613361156AVACCINATIONS 2021-05-13 COVID-19 PFIZER VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrބDWDHr3$DW3DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrބHr3$..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1156 11561336115613361156A VACCINATIONS 2021-06-03 COVID-19 PFIZER VACCINE TOZINAMERAN 15268625001 YY DW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHrބDWDHr3$DW3DW..DV.DW... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrބHr3$..Placebo APlacebo A . .Placebo Placebo .NYFollow Up 1 A0A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH09meningococcus B, multicomponent vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH05other meningococcal polyvalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH06meningococcus B, outer membrane vesicle vaccine B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH07meningococcus C, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH08meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugatedB.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH04meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH10meningococcus A, purified polysaccharides antigen conjugated B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH03meningococcus A,C, bivalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH02other meningococcal monovalent purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561349115613491156AVACCINATIONS 2021-06-05 MENINGOCOCCAL (GROUP A, C, Y, W-135) MENINGOCOCCAL VACCINE A/C/Y/W 06559307001 YY DW B. .MENINGOCOCCAL VACCINES J07AHMENINGOCOCCAL VACCINE A/C/Y/W JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07ABACTERIAL VACCINES J07AHMENINGOCOCCAL VACCINES J07AH01meningococcus A, purified polysaccharides antigen B.. REPEAT SCREENING 1 WHODDG B3 v202103AYEARSMAWHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DWDHrDW"DHr<DW@DW..DW.DW"... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHr<..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYAfter unblinding and before Vaccination 3A@A C4591001C4591001 1156 11561353115613531156AVACCINATIONS 2021-06-10 BNT162B2 COVID-19 PFIZER TOZINAMERAN 15268625001 Y YDW B. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES B.. OPEN LABEL TREATMENTWHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDߘHr&DWDHHsrDW?DWDWDXeDW.DW#DW.. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr&Hr$HsrHsrPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 3 APA0C4591001C4591001 1156 11561359115613591156AVACCINATIONS 2021 PFIZER COVID-19 VACCINE TOZINAMERAN 15268625001Y DW Mp. .OTHER VIRAL VACCINES J07BXTOZINAMERAN JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BXOTHER VIRAL VACCINES ... WHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWDtHr2tDWDHsndDWGDWDWDXbDW.DW%DW.. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr2tHrdHsndHsndPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW B. . PREDNISONE AALIMENTARY TRACT AND METABOLISM A07ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTSA07EINTESTINAL ANTIINFLAMMATORY AGENTS A07EACORTICOSTEROIDS ACTING LOCALLYA07EA03prednisone B.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD|Hr{DWD(Hs٨DWFDWDWDXfDW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr"Hsw Hs٨Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW B. . PREDNISONE HSYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINSH02CORTICOSTEROIDS FOR SYSTEMIC USE H02ACORTICOSTEROIDS FOR SYSTEMIC USE, PLAINH02ABGLUCOCORTICOIDS H02AB07prednisone B.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD|Hr{DWD(Hs٨DWFDWDWDXfDW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr"Hsw Hs٨Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW B. . PREDNISONE SSENSORY ORGANS S01OPHTHALMOLOGICALS S01BANTIINFLAMMATORY AGENTS S01BACORTICOSTEROIDS, PLAIN B.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD|Hr{DWD(Hs٨DWFDWDWDXfDW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr"Hsw Hs٨Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1223 12231273122312731223ACORTICOSTEROIDS 2021-06-13 prednisone PREDNISONE 00044701001 Y YDW B. . PREDNISONE DDERMATOLOGICALS D07CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07ACORTICOSTEROIDS, PLAIN B.BORAL mgBIDONGOINGLAST SUBJECT ENCOUNTEROPEN LABEL TREATMENTWHODDG B3 v202103AYEARSMAWHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DWD|Hr{DWD(Hs٨DWFDWDWDXfDW.DW%DWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr{Hr"Hsw Hs٨Placebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 4 A`A@C4591001C4591001 1270 12701207127012071270AVACCINATIONS 2021-02-03 FLUARIX QUADRIVALENT (INFLUENZA VACCINE) INFLUENZA VACCINE INACT SPLIT 4V 01389806001 YY DW* B2. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B2.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYBNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30DVDpHrDW D<HrfDW*DW..DV.DW ... . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHrHrf..BNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)A . .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .YYVaccination 2 A A C4591001C4591001 1270 12701221127012211270AVACCINATIONS 2021-02-03 INFLUENZA VACCINE (FLUARIX QUADRIVALENT) INFLUENZA VACCINE INACT SPLIT 4V 01389806001 YY DW* B0. .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen B0.. FOLLOW-UP WHODDG B3 v202103AYEARSFA WHITE AWHITE AYPlacebo PLACEBO Placebo PLACEBO DVDHr4DWDHshPDW*DWDWDXjDV.DWDWDW. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr4HrŚHs~.HshPPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYVaccination 2 A A C4591001C4591001 1270 12701237127012371270AVACCINATIONS 2020-12-21 Fluarix Quadrivalent (Influenza Vaccine) INFLUENZA VACCINE INACT SPLIT 4V 01389806001Y DV . .INFLUENZA VACCINES J07BBINFLUENZA VACCINE INACT SPLIT 4V JANTIINFECTIVES FOR SYSTEMIC USE J07VACCINES J07BVIRAL VACCINES J07BBINFLUENZA VACCINES J07BB02influenza, inactivated, split virus or surface antigen .. SCREENING WHODDG B3 v202103AYEARSFA AMERICAN INDIAN OR ALASKA NATIVEA0AMERICAN INDIAN OR ALASKA NATIVEA0YPlacebo PLACEBO Placebo PLACEBO DWDHr$DWDtHstDWZDWDWDXgDW..DW.. . . A@Phase 3DWNNA12-15 YearsA12-15 YearsAHr$Hr$HstHstPlacebo APlacebo ABNT162b2 Phase 2/3 (30 mcg)ABNT162b2 Phase 2/3 (30 mcg)APlacebo BNT162b2 (30 (*ESC*){unicode 03BC}g) .NYPre-Vaccination .